2Grimm D, Thimme R, Blum HE. HBV life cycle and novel drug targets. Hepatol Int 2011, 5: 644-53.
3Negro F. Management of chronic hepatitis B: an update. Swiss Med Wkly 2011, 141: w13264.
4Leemans WF, Ter Borg M J, de Man RA. Review article: success and failure of nucleoside and nucleotide analogues in chronic hepatitis B. Aliment Pharmacol Ther 2007, 26 Suppl 2: 171-82.
5Lucifora J, Zoulim F. The life cycle of hepatitis B virus and antiviral targets. Future Viro12011, 6: 599-614.
6Choi IG, Yu YG. Interaction and assembly of HBV structural proteins: novel target sites of anti-HBV agents. Infect Disord Drug Targets 2007, 7: 251-6.
7Chen H J, Wang WL, Wang GF, Shi LP, Gu M, Ren YD, et al. Rational design and synthesis of 2,2-bisheterocycle tandem derivatives as non-nucleoside hepatitis B virus inhibitors. Chem Med Chem 2008, 3: 1316-21.
8Deres K, Schroder CH, Paessens A, Goldmann S, Hacker H J, Weber O, et al. Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids. Science 2003, 299: 893-6.
9Ying C, Li Y, Leung CH, Robek MD, Cheng YC. Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue. Proc Natl Acad Sci U S A 2007, 104: 8526-31.
10Wu C, DengW, Deng L, Cao L, Qin B, Li S, et al. Amino acid substitutions at positions 122 and 145 of hepatitis B virus surface antigen (HBsAg) determine the antigenicity and immunogenicity of HBsAg and influence in vivo HBsAg clearance. J Virol 2012, 86: 4658-69.
